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The understanding of human normal and leukaemic myelo-
poiesis has been advanced by the development of mono-
clonal antibodies. The most immunogenic structure for mice
on the surface of human myeloid cells is 3-fucosyl-N-
acetyllactosamine (FAL) and the majority of myeloid specific
monoclonal antibodies designated as CD 15 react with this
determinant (Geurts van Kessel et al., 1984; Majdic et al.,
1984; Gooi et al., 1985; Foon & Todd, 1986). The typical
representative of this class of antibodies is VIM-D5 which
reacts with myeloid cells but not with monocytes. The other
important antibody detecting myelomonocytic cell surface
antigen M2 is VIM-2. A valuable marker of granulocytic
differentiation is also nonspecific cross-reacting antigen
(NCA) (Burtin et al., 1979,1980; Heumann et al., 1979;
Wahren et al., 1980; Noworolska et al., 1985). To our
knowledge no data are available concerning the relationship
and sequence of appearance of the antigens detectable by
VIM-2 and VIM-D5 monoclonal antibodies and NCA
expression.
In this study we report that the membrane distribution of
epitopes reactive with VIM-2 and VIM-D5 in acute and
chronic myelocytic leukaemias is dependent on various stages
of granulocyte differentiation. Emphasis is placed on
determining the interrelationship between VIM-2 and VIM-
D5 specificities and cytoplasmic NCA-positivity (cNCA)
studied by a double fluorescence technique taking into
account the maturation of leukaemic granulocytes isolated
by density gradient centrifugation.
Ten cases of AML subclassified according to the FAB-
Cooperative Group criteria (Bennet et al., 1976) were
studied. Five cases of CGL were also investigated and 2 of
these subjects were in myeloblastic crisis (CGL-BC). The
diagnosis was established by standard morphological and
cytochemical staining. All immunological tests were
performed on peripheral blood cells of leukaemic patients
before treatment. Monoclonal antibodies VIM-2 and VIM-
D5 (CD 15) were kindly provided by Prof. W. Knapp
(Department of Immunology, University of Vienna), (Majdic
et al., 1981; Majdic et al., 1984). Anti-NCA serum was
obtained by immunization of goats with purified NCA
(Krop-W4torek et al., 1983). Before use in immuno-
fluorescence tests it was absorbed on columns prepared by
coupling purified CEA to CNBr-activated Sepharose 4B.
To separate the myelocytic cells according to the matura-
tion stage, density-gradient centrifugation was applied (Ficoll-
Uropoline 1.05-1.12gml-1) according to Harlozifnska et al.,
(1982). This method was used for all CGL and CGL-BC
but only in 3 AML cases. Remaining cells from 7 AML
patients were isolated in 3% dextran T500 (Pharmacia AB,
Uppsala, Sweden) because the WBC count was low and blast
content was >60%.
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The reactivity of the three antibodies (VIM-2, VIM-D5,
anti-NCA) was evaluated on each cell fraction by immuno-
fluorescence. Assessment of antibodies on living cells was
made at a dilution of 1:80 and the cells were stained with
fluorescein isothiocyanate (FITC)-labelled swine anti-mouse
immunoglobulin (Sevac, Prague, Czechoslovakia). The
preparations were finally washed and mounted in a mixture
of polyvinyl alcohol and glycerol (Freer, 1984). The
expression of cNCA was estimated on cell cytocentrifuge
preparations as described earlier by Noworolska et al.,
(1986). For double fluorescent staining the cytospin
preparations of the cells which had been subjected to vital
staining with VIM-D5 and VIM-2 were fixed in methanol
and incubated with anti-NCA serum. After washing to
remove unbound antibodies, the smears were treated with
tetramethylrhodamine isothiocyanate(TRITC)-labelled rabbit
anti-goat IgG (Miles Lab. Ltd., Slough, UK). Surface
antigens detectable by monoclonal antibodies expressed
green fluorescence and cNCA showed red staining. Double
fluorescence technique was also applied to study the surface
expression of the antigens. NCA was detected with TRITC-
labelled rabbit anti-goat Ig and M2 or FAL-determinants
with FITC-conjugated swine anti-mouse immunoglobulin as
the second layer. All preparations were evaluated in an
Opton type III Photomicroscope using incident-light
excitation. The control studies included: (a) PBS, (b) normal
goat serum as a first layer and TRITC- or FITC-labelled
rabbit anti-goat IgG as a second layer, (c) normal mouse
serum as a first layer and FITC-labelled swine anti-mouse
immunoglobulin as a second layer.
The results of VIM-2 and VIM-D5 binding and cyto-
plasmic NCA content in AML patients are presented in
Figure 1. The percentage of positive Ml AML blasts with all
of the antibodies was <5%. The percentage of cells reacting
with VIM-2 and VIM-D5 in AML M2 type clearly increased
and was usually higher in comparison to NCA+ cells. In one
case of M3 AML considerable amounts of VIM-D5
and cNCA-positivity were found. Unfortunately VIM-2
binding was not estimated. The myelomonocytic and
monocytic leukaemias showed the presence of M2 antigen in
a significant percentage of blasts, but the reactivity with
VIM-D5 antibody and anti-NCA serum was always <15%.
The estimation of the three antigens on density fractions of
M2 type AML cells showed that independently of density
layers the percentage of positive blasts was similar (Figure
2). This means that expression of antigens detectable by
VIM-2 and VIM-D5 antibodies did not change in relation to
various densities of blasts within 1.05-1.07gml 1. It is
interesting that some cytological differences were noted
between blasts at these interfaces. The blasts focused in
1.05 gml-1 showed a lower stage of maturity. In comparison
to the blasts from the 1.06 and 1.07gml-1 layers, they were
larger with more abundant basophilic cytoplasm. In this
patient NCA expression was undetectable.
The analysis of antigen distribution in cells of CGL
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Figure 1 VIM-2 and VIM-D5 reactivity and cNCA distribution in blasts of acute myelocytic leukaemias (dextran isolation):
1 =VIM-2, 2=VIM-D5, 3=cNCA, thick vertical line = % of blasts.
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Figure 2 VIM-2 and VIM-D5 reactivity and cNCA distribution
in AML M2 blasts separated by Ficoll-Uropoline density
gradient centrifugation: 1 =VIM-2, 2=VIM-D5, 3=cNCA,
thick vertical line= % of blasts.
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Figure 3 VIM-2 and VIM-D5 reactivity and cNCA distribution
in CGL and CGL-BC cells (1.05 gml - I Ficoll-Uropoline
fraction): 1 =VIM-2,2=VIM-D5,3=cNCA,thickverticalline = %
of blasts.
Table I VIM-2 and VIM-D5 reactivity and sNCA and cNCA content in peripheral blood cells
separated by density gradient centrifugation in CGL-BC patient
Wright-Giemsa
morphologya (%) IF test
Density layer Blasts Myel Band VIM-2 VIM-D5 sNCA cNCA
(gml-1) Pro Mta PMN positive cells (%)
1.05 32.0 45.0 23.0 68.0 57.0 45.0 67.0
1.06 8.0 48.0 44.0 64.0 58.0 61.0 86.0
1.07 0.0 28.0 72.0 67.0 64.0 75.0 92.0
1.08 4.0 21.0 75.0 72.0 69.0 87.0 95.0
1.09 0.0 13.0 87.0 71.0 70.0 90.0 96.0
1.105 0.0 5.0 95.0 68.0 68.0 67.0 95.0
dextran 9.0 20.0 71.0 67.0 69.0 69.0 89.0
aBlasts =myeloblasts, Pro=promyelocytes, Myel =myelocytes, Mta=metamyelocytes,
Band=band forms, PMN=polymorphonuclear neutrophils.
patients isolated in the 1.05 gml- Ficoll-Uropoline fraction
focusing immature granulocytes showed that all three
antigens were detectable in a high percentage of these cells
(Figure 3). It was interesting that the number of cells with
antigenic determinants detectable with VIM-2 was on
average higher than the proportion of VIM-D5-positive cells.
The number of NCA expressing cells showed individual
differences among the patients studied. Table I shows the
results of separation of leukocytes in an individual patient
with CGL-BC using density gradient centrifugation. In each
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cell fraction the expression of M2, FAL structure detectable
by VIM-D5 antibody, cNCA, and sNCA was estimated. The
content of VIM-2 and VIM-D5 reactive antigens was almost
at the same level independently of the density layer and
morphological maturity of the granulocytes. The differences
between the low density layers focusing the majority of
blasts and myelocytes and the high density layers with
mature forms of granulocytes amounted to not more than
13% of fluorescing cells. In contrast, the number of sNCA
as well as cNCA expressing cells increased with maturity of
the cells, but in the fraction 1.105gml-1, the percentage of
sNCA-positive cells was significantly reduced, probably as a
.result of increased ability of most mature granulocytes to
release surface NCA into the circulation. A percentage of
nonfluorescent cells was always observed regardless of the
antigen studied, the type of myelocytic leukaemia and the
stage ofgranulocytic maturation.
Double fluorescent staining showed that myeloid cells
could simultaneously express M2 or FAL-determinants and
sNCA on their surface. A proportion of cells expressing only
one antigen was always observed (Figure 4a). Similarly,
double staining for cNCA and surface antigens detectable by
VIM-2 or VIM-D5 was also performed (Figure 4b). The
results revealed that a considerable proportion of leukaemic
cells reacted with both antibodies, however two additional
subpopulations of cells could be clearly distinguished: one
expressing only cNCA (35-45%), and another carrying M2
or FAL determinants only (5-25%).
The comparison of antigens detectable by VIM-2 and
VIM-D5 antibodies, and NCA expression in AML and CGL
cells confirmed the heterogeneity of myeloid leukaemias
(Lange et al., 1984; Pessano et al., 1984; Ross, 1985). We did
not observe any competitive binding between these antigens.
The distribution of M2 and FAL determinants was studied
on living cells only because the available monoclonal
antibodies were directed against surface antigens (Majdic et
al., 1984; Gooi et al., 1985) and NCA expression on living
and fixed cells because this antigen could be easily detected
after fixation (Noworolska et al., 1985). According to other
data (Majdic et al., 1984; Pessano et al., 1984) a leukaemia
was classified as antigen positive if > 15% of cells were
reactive by immunofluorescence after treatment with a
particular monoclonal antibody.
Our data show the coexistence of antigen positive and
antigen negative cells within a given leukaemic population
and even in the leukaemic cell fraction of the same density.
This subpopulation antigenic heterogeneity was also
100
80
60
s.5L
40 20
>
- _ - EZ -'M2
o00 - NCA
I- - M2 + NCA
80
_60
40 4
20
Dextran 1.05 1.06 1.07. 1.08 1.09 1.105
gml-1 F-U
Figure 4 Distribution of M2 and sNCA (a) and M2 and cNCA
(b) in Ficoll-Uropoline density gradient fractions of a patient
with myeloid CGL-BC (double fluorescence).
confirmed by double fluorescence staining. The surface
phenotype of the leukaemic population in any individual
patient probably comprises numerous subpopulations that
express none, some, or all antigens characterizing normal
haemopoietic differentiation (Pessano et al., 1984).
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